NCT06033183 Integrative Molecular Analysis of Individual Radiosensitivity in Pediatric Oncology
| NCT ID | NCT06033183 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Neolys |
| Condition | Radiosensitivity |
| Study Type | INTERVENTIONAL |
| Enrollment | 100 participants |
| Start Date | 2023-12-02 |
| Primary Completion | 2027-08-30 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 100 participants in total. It began in 2023-12-02 with a primary completion date of 2027-08-30.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Analysis of the individual radiosensitivity in pediatric oncology
Eligibility Criteria
Inclusion Criteria: * Minor patient treated for a brain tumor, Ewing tumor, malignant mesenchymal tumor, neuroblastoma, nephroblastoma, Hodgkin's lymphoma treated with radiotherapy (+/- chemotherapy) for curative purposes. * Children or adolescents \> 3 years old and \< 18 years old * Patient with an indication for radiotherapy as part of the primary tumor local control strategy * Theoretical indication for radiotherapy in standard fractionation (1.8 Gy to 2.2 Gy / fraction: 5 fr/week) whatever the technique and the particle used * Patient affiliated with a social security scheme * Patient and/or parents or holders of parental authority having dated and signed an informed consent Exclusion criteria: * Patients with contraindications to blood sampling * Patients with contraindications to radiotherapy * Palliative radiotherapy * Patient with previous RT treatment in the same area (re-irradiation) * Patient with an indication of hypofractionated RT * Patient follow-up not possible * Persons deprived of liberty or under guardianship (including curatorship) Exclusion Criteria: \-
Contact & Investigator
Frequently Asked Questions
Who can join the NCT06033183 clinical trial?
This trial is open to participants of all sexes, aged 3 Years or older, up to 18 Years, studying Radiosensitivity. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06033183 currently recruiting?
Yes, NCT06033183 is actively recruiting participants. Contact the research team at spereira@neolys-diagnostics.fr for enrollment information.
Where is the NCT06033183 trial being conducted?
This trial is being conducted at Caen, France, Lille, France.
Who is sponsoring the NCT06033183 clinical trial?
NCT06033183 is sponsored by Neolys. The trial plans to enroll 100 participants.